IDH1 and acute myeloid leukemia: R132C/S280F IDH1 has been observed in AML patients treated with the R132C IDH1 inhibitors enasidenib or ivosidenib and manifests resistance because it restores IDH1 variant–catalyzed 2HG production (11, 12, 53).